# Celula-China

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celula-china

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.celula-china.com
- Latest round: Series B (Feb 20, 2021)
- Investors on record: 7

## About

Based in Chengdu, China and established in 2013, Celula-China operates as a gene detection company which focuses on oncology and reproductive health. It provides related diagnostic reagent and equipment. The company has established a production and service base of more than 5,000 square meters, branch offices in Shanghai, Zhuhai, and offices in Beijing and many provinces of China respectively.

The company's main products include non-invasive prenatal testing products and Sparrow flow cytometry. Among them, the non-invasive prenatal testing products are capable of efficiently analyzing the genetic defects and health status of fetuses.

## Funding rounds

- Series B, Feb 20, 2021 — Guigu Xiachuang Capital, Chengdu Shenghua Chuanghe Investment
- Series B, Sep 7, 2020 — Celula, CD Capital, Jinyuan Kuntong Equity Investment Management, Hanne Capital
- Series A, Oct 9, 2018 — CD Capital, Jinyuan Kuntong Equity Investment Management, Bioching Capital

## Investors

- CD Capital — Series A, Series B
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series A, Series B
- Bioching Capital (https://capitalatlas.ai/funds/bioching-capital) — Series A
- Celula — Series B
- Hanne Capital (https://capitalatlas.ai/funds/hanne-capital) — Series B
- Guigu Xiachuang Capital — Series B
- Chengdu Shenghua Chuanghe Investment — Series B